In this episode of the Heart Failure Beat, our hosts sit down with Dr. James Fang, immediate past president of the Heart Failure Society of America, to discuss highlights from his term and the advancements shaping heart failure care. Dr. Fang reflects on major scientific breakthroughs, including the SEQUOIA-HCM and FINEARTS-HF trials, and the role of GLP-1 agonists. He also emphasizes the societal importance of accessible treatments, especially with recent legislative changes impacting drug affordability. Dr. Fang highlights initiatives like the Heart Failure Research Foundation’s support for early-career investigators and the Journal of Cardiac Failure's expansion into Open Access, which together aim to foster collaboration and drive innovation. Tune in for insights on pivotal developments, the future of heart failure as a specialty, and the Society’s commitment to fostering a multidisciplinary approach to patient care.